MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications ...

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), ...

MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

CHICAGO, January 07, 2025--MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications CHICAGO, December 16, 2024--MAIA ...

Health-care companies rose as a reported U.S. death from bird flu stoked fears of a new pandemic, boosting shares of vaccine makers.

After hours: 7:55:07 p.m. EST ...

F5, Inc. announced it will report its first quarter fiscal year 2025 financial results on Tuesday, January 28, 2025 following the market close. F5 also will host a live webcast to discuss its results ...

Gradient AI, a leading enterprise software provider of artificial intelligence (AI) solutions in the insurance industry, today announced that Evolution Risk Partners has successfully adopted Gradient ...